InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) CEO Discusses UST(TM) Platform, Early Access Program on Stock Day Podcast

Pressure BioSciences (OTCQB: PBIO) (“PBI”) is a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables and specialty testing services for the worldwide life sciences markets and other industries. The company was featured in a recent episode of The Stock Day Podcast, where its CEO Richard T. Schumacher joined Stock Day host Sever Copley to discuss PBI’s Ultra Shear Technology(TM)(“UST(TM)”) for the processing of nanoemulsions. The company has seven issued UST patents to date, including two in the U.S., with many more expected to follow. “The oil in these emulsions typically contains the valuable active ingredients, which could be a pharmaceutical or a nutraceutical, a functional cosmetic ingredient, or important food and beverage nutrients. And in UST-produced nanoemulsions with extremely tiny and controlled droplet sizes, these components suddenly become nearly 100% bioavailable, allowing the body to absorb them much more efficiently, while the solution also becomes visibly transparent – offering heightened smell, taste and texture benefits. An additional benefit is that the intense shear forces of UST also shred many microbial contents, providing enormously extended room temperature and cold-chain shelf life and stability for foods, beverages and many other products,” Schumacher said in the interview. “We plan to support four or five companies in the Early Access Program… We intend on contracting with these companies in the upcoming weeks and months and expect to get several more products onto the market with UST benefits incorporated by the end of 2022… We are confident that UST will powerfully differentiate these companies’ products into leadership roles in their respective markets. Flowing from this, our lease and license model for UST commercialization is expected to launch the revenue streams for PBI onto a dramatic new trajectory by early to mid-2023.”

To view the full press release, visit https://ibn.fm/eBKM2

About Pressure BioSciences Inc.

Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information about the company, visit www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.